



3M

Cavilon™

Skin Care Solutions

**Cleanse, protect
and restore skin
in one easy step.**

3M™ Cavilon™ Contenance Care Wipes

What is Incontinence-Associated Dermatitis?

Incontinence-Associated Dermatitis (IAD) is a painful and problematic skin injury that results from exposure to urine or stool. Moisture and irritants trigger inflammation with damage occurring in a “top-down” fashion.¹

What is the impact of IAD?

For you, IAD:

- Creates a poor patient or resident experience
- Increases the burden and cost of care

For your patient or resident, IAD:

- Is painful
- Increases the risk of complications such as secondary infections and pressure injuries


IAD is common



IAD is a risk factor for pressure injuries


Incontinence has long been considered a risk factor for pressure injuries – moisture on the skin increases friction and friction is a component of shear force, which can contribute to pressure injury – especially in the

sacroccygeal area. Recently, IAD has been recognised as a risk factor⁴ with the likelihood of developing a pressure injury increasing with the severity of IAD.⁵



Who is at risk for IAD?

All patients or residents with incontinence are at risk but those with mixed incontinence are the most vulnerable especially when stools are liquid or diarrhoea is present.⁶



3M™ Cavilon™ Continance Care Wipes

A no-rinse cleanser, moisturiser and barrier in a strong yet gentle pre-moistened cloth. This multi-purpose product contains mild surfactants for cleansing along with soothing skin conditioning ingredients.

- One-step incontinence care helps to reduce caregiver time and effort by combining three steps in one
- Contains moisture repelling dimethicone
- Hypoallergenic and pH balanced
- Parabens-free, aloe-free and fragrance-free
- Compatible with chlorhexidine gluconate (CHG)⁷



Recommended standard of care

Evidence suggests that disposable wipes are more effective for prevention of IAD than a skin care regime combining neutral soap and water.⁸ Cavilon Continance Care Wipes are a no-rinse cleanser, moisturiser and barrier in a strong yet gentle pre-moistened cloth. This multi-purpose product contains mild surfactants for cleansing along with soothing skin conditioning ingredients. They contain moisture repelling dimethicone (3%). One-step incontinence care helps to reduce caregiver time and effort by combining three steps in one.

Frequent skin cleansing with water and soap is detrimental to skin barrier function by damaging the corneocytes, removing lipids, increasing dryness and creating friction.⁹ Aggressive cleansing technique

(e.g. using regular washcloths) can increase frictional forces and abrade the skin.¹⁰ Both may contribute to the development of IAD.⁶ Furthermore, infection control issues associated with the use of wash basins have been identified.¹¹

In addition to providing a benefit for skin, use of no-rinse skin cleansers has been shown to save staff time and improve efficiency.¹²⁻¹⁴ Continance care wipes are made of smooth material to reduce friction damage. These have been found to enhance adherence to protocols, reduce burden of care and improve staff satisfaction.⁹

The evidence

A defined (structured) skin care regimen, including the use of a soft pre-moistened washcloth impregnated with a 3% dimethicone skin protectant, resulted in a significantly reduced prevalence of IAD and a trend towards less lesions.¹⁰ This study provides evidence supporting the use of a 3-in-1 perineal care washcloth as more effective than standard care including water and a pH neutral soap for IAD prevention and treatment.

Key elements of an IAD prevention program⁶

Continence care wipes (i.e. 3-in-1 products) that are intended to cleanse, protect and restore may have the advantage of simplifying care by combining products to reduce the number of steps involved, saving clinician/caregiver time and potentially encouraging adherence to the regime.¹⁵⁻¹⁷

1.

Cleanse

Regular cleansing is critical, but alkaline soaps can disrupt the natural acid mantle of the skin, leading to skin damage. Gentle cleansing with a pH-balanced, no-rinse product removes harmful irritants. Cavilon Continence Care Wipes are pH-balanced.

2.

Protect

An application of a waterproof, durable barrier keeps skin protected through episodes of exposure. Cavilon Continence Care Wipes contain dimethicone for protection from body fluids associated with incontinence.

3.

Restore

For intact skin, the addition of moisturising ingredients can improve skin health. Cavilon Continence Care Wipes contain moisturising ingredients to help maintain the skin's natural barrier.



Principles of CLEANSE in the prevention and management of IAD⁶


Principle	Possible with Cavilon Continence Care Wipes
Cleanse daily and after every episode of faecal incontinence	•
Use gentle technique with minimal friction, avoid rubbing/scrubbing of skin	•
Avoid standard (alkaline) soaps	•
Choose a gentle, no-rinse liquid skin cleanser or pre-moistened wipe (designed and indicated for incontinence care), with a pH similar to normal skin	•
If possible, use a soft, disposable non-woven cloth	•
Gently dry skin if needed after cleansing	•

Spend less time cleaning patients' skin after episodes of incontinence – while you help them feel cleaner, more comfortable and protected.

Cavilon Continence Care Wipes are a convenient, time-saving alternative to plain soap and water. These disposable, hypoallergenic wipes are designed to gently cleanse, moisturise and provide an effective barrier against moisture and bodily fluids. Used regularly, they may be an effective first line of defence against painful and persistent Incontinence-Associated Dermatitis (IAD).

Skin Protection Plan – Managing Incontinence-Associated Dermatitis

The best practice principles⁶ recommend that additional skin protection can be used for the prevention of IAD if required, and, when managing IAD if there is worsening erythema/skin condition. In these cases, we recommend that you cease use of 3M™ Cavilon™ Continance Care Wipes and commence use of 3M™ Cavilon™ Advanced Skin Protectant, replacing the Cavilon Continance Care Wipes with water for cleansing. The skin protection plan below explains which product to use, depending on the patient's clinical presentation.

Clinical Presentation ⁶	Cleansing			Skin Protection		
	Risk	What	When	What	When*	How much
 	Low		After every incontinent episode	No additional protection required		
	High	Cleansing product that doesn't include a barrier			Twice a week	Even coat
 	Low		After every incontinent episode	No additional protection required		
	High	Cleansing product that doesn't include a barrier			Twice a week	Even coat
 		Cleansing product that doesn't include a barrier	After every incontinent episode		Twice a week	Even coat

- If a fungal infection occurs, cease use of 3M™ Cavilon™ Skin Care products and treat the skin with an anti-fungal product as directed by your facility procedure. Once the use of an antifungal cream has been discontinued, resume the use of Cavilon Skin Care products.

- Do not use cleansing products containing a barrier (eg 3-in-1 wipes) when using Cavilon Advanced Skin Protectant
- 3M™ Cavilon™ Durable Barrier Cream or 3M™ Cavilon™ No Sting Barrier Film are alternate options for additional skin protection, if Cavilon Advanced

Skin Protectant is not available. These products may be used in combination with Cavilon Continance Care Wipes.

* More or less frequent application may be required, depending on the frequency of incontinent episodes.

Ordering Information

Product Code	Product	Size	Items/Pack	Packs/Case
9274	3M™ Cavilon™ Continance Care Wipes	20cm x 30cm	8	12

For more information

For more information, please call: 1300 363 878 (Australia) or 0800 80 81 82 (New Zealand) or visit our websites:

3M.com.au/Cavilon 3M.co.nz/Cavilon

References

1. Thayer DM, Rozenboom B, Baranoski S. "Top-down" Skin Injuries: Prevention and Management of Moisture-Associated Skin Damage, Medical Adhesive-related Skin Injury (MARS) and Skin Tears. In: Doughty D and McNichol LL eds. Wound Management. Philadelphia, PA Wolters Kluwer 2016. p283.
2. Nix D, Haugen V (2010) Prevention and management of Incontinence-Associated Dermatitis. Drugs Aging 27(6): 491-6.
3. Gray M, Bartos S. Incontinence-Associated Dermatitis in the Acute Care Setting: A Prospective Multi-Site Epidemiological Study. Presented at the Symposium on Advanced Wound Care. May 2013.
4. Beeckman D, Van Lancker A, Van Hecke A, Verhaeghe S. A systematic review and meta-analysis of Incontinence-Associated Dermatitis, incontinence, and moisture as risk factors for pressure ulcer development. Res NurseHealth 2014;37: 204-18.
5. Park KH. The effect of a silicone border foam dressing for prevention of pressure ulcers and Incontinence-Associated Dermatitis in intensive care unit patients. J WOCN 2014; 41(5): 424-29.
6. Beeckman D et al. Proceedings of the Global IAD Expert Panel. Incontinence-Associated Dermatitis: moving prevention forward. Best Practice Principles. Wounds International 2015.
7. 3M data on file
8. Doughty D, Junkin J, Kurz P et al. Incontinence-associated dermatitis. Consensus statements, evidence-based guidelines for prevention and treatment, current challenges. J WOCN 2012; 39(3): 303-15.
9. Beeckman D, Schoonhoven L, Verhaeghe S, et al. Prevention and treatment of incontinence-associated dermatitis: literature review. J Adv Nurs 2009; 65(6): 1141-54.
10. Beeckman D, Verhaeghe S, Defloor T, et al. A 3-in-1 perineal care washcloth impregnated with dimethicone 3% versus water and pH neutral soap to prevent and treat incontinence-associated dermatitis. J WOCN 2011; 38(6): 627-34.
11. Johnson D, Lineaweaver L, Maze C. Patients' bath basins as potential sources of infection: a multicenter sampling study. Am J Crit Care Nurses 2009; 8:31-40.
12. Beeckman D, DeFloor T, Verhaeghe S, et al. What is the most effective method of preventing and treating incontinence associated dermatitis? Nursing Times 2010; 106(38): 22-25.
13. Lewis-Byers K, Thayer D, Kahl A. An evaluation of two incontinence skin care protocols in a long-term care setting. Ostomy Wound Manage 2002; 48(12):44-51.
14. Warshaw E, Nix D, Kula J, et al. Clinical and cost-effectiveness of a cleanser protectant lotion for treatment of perineal skin breakdown in low-risk patients with incontinence. Ostomy Wound Manage 2002; 48(6): 44-51
15. Gray M, Beeckman D, Bliss DZ, et al. Incontinence-associated dermatitis: a comprehensive review and update. J WOCN 2012; 39(1): 61-74.
16. Beeckman D, Woodward S, Gray M. Incontinence-associated dermatitis: step-by-step prevention and treatment. Br J Community Nurs 2011; 16(8): 382-89.
17. Driver DS . Perineal dermatitis in critical care patients. Critical Care Nurse 2007; 27(4): 42-46.



3M Australia Pty Limited
ABN 90 000 100 096
Building A, 1 Rivett Rd
North Ryde NSW 2113
Phone 1300 363 878

3M New Zealand Limited
94 Apollo Drive
Rosedale, Auckland 0632
New Zealand
Phone 0800 80 81 82

3M and Cavilon are trademarks of 3M Company. Please recycle.
© 3M 2022. All rights reserved. AV011451976. ANZ_70-2013-1504-4.